Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Julius S, et al. Among authors: smith b. Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9. Lancet. 2004. PMID: 15207952 Clinical Trial.
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Schmieder RE, et al. Among authors: smith b. Circulation. 2009 Jan 27;119(3):417-25. doi: 10.1161/CIRCULATIONAHA.107.750745. Epub 2009 Jan 12. Circulation. 2009. PMID: 19139391 Clinical Trial.
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JJ. Pitt B, et al. Among authors: smith ba. Eur J Heart Fail. 2011 Jul;13(7):755-64. doi: 10.1093/eurjhf/hfr034. Epub 2011 Apr 4. Eur J Heart Fail. 2011. PMID: 21467028 Free article. Clinical Trial.
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Solomon SD, et al. Among authors: smith ba. Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214. Epub 2009 Jan 19. Circulation. 2009. PMID: 19153265 Clinical Trial.
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
Pouleur AC, Uno H, Prescott MF, Desai A, Appelbaum E, Lukashevich V, Smith BA, Dahlöf B, Solomon SD; ALLAY Investigators. Pouleur AC, et al. Among authors: smith ba. J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):483-90. doi: 10.1177/1470320311414453. Epub 2011 Jul 11. J Renin Angiotensin Aldosterone Syst. 2011. PMID: 21746765 Free article. Clinical Trial.
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
Vardeny O, Pouleur AC, Takeuchi M, Appelbaum E, Verma A, Prescott M, Smith B, Dahlof B, Solomon SD; ALLAY Investigators. Vardeny O, et al. Among authors: smith b. J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):265-72. doi: 10.1177/1470320312437893. Epub 2012 Mar 13. J Renin Angiotensin Aldosterone Syst. 2012. PMID: 22415888 Free article. Clinical Trial.
12,410 results
You have reached the last available page of results. Please see the User Guide for more information.